# Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer

> **NCT06783140** · PHASE2,PHASE3 · RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 10 (estimated)

## Conditions studied

- Pancreatic Cancer, Advanced or Metastatic
- BRCA1/2 Mutation
- PALB2 Gene Mutation

## Interventions

- **DRUG:** Nab paclitaxel
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT06783140
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-10
- **Primary completion:** 2031-06-02
- **Final completion:** 2031-06-02
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06783140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06783140, "Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06783140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*